Active, not recruitingPHASE1, PHASE2NCT03016377

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
UNC Lineberger Comprehensive Cancer Center
Principal Investigator
Natalie S Grover, MD
UNC Lineberger Comprehensive Cancer Center
Intervention
iC9-CAR19 cells(biological)
Enrollment
17 enrolled
Eligibility
3-70 years · All sexes
Timeline
20122037

Study locations (1)

Collaborators

Bellicum Pharmaceuticals · The Leukemia and Lymphoma Society

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03016377 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials